

## ASX ANNOUNCEMENT

# Exopharm to Present at Key Exosome Industry Event

**16 November 2021, Melbourne, Australia:**

Exopharm Limited (ASX:EX1), a clinical-stage, global leader in exosome medicines, announces that Chief Commercial Officer and Deputy CEO, Dr Chris Baldwin, will present at the 3<sup>rd</sup> *Exosome Based Therapeutic Development Digital Summit* on 16 November (2:00PM US Eastern Time, 6:00AM AEDT).

The presentation entitled "*Recent Advances in Cation Exchange Purification of Exosomes*" will highlight recent developments that Exopharm has made with its LEAP technology for the purification of exosomes.

The Summit, subtitled "*Successfully Source, Characterize & Load Clinically Relevant Exosome Therapeutics for Accelerated Development & Commercialization*", is the key international industry-dedicated exosome meeting.

A copy of Dr Baldwin's presentation slides is attached.

*By the Managing Director - this announcement has been authorised for release by the Managing Director.*

### **Company and Media Enquiries:**

*Join our mailing list to receive updates:*

<http://exo.ph/ExoMails>

[www.exopharm.com](http://www.exopharm.com)

P: +61 (0)3 9111 0026

Rudi Michelson

Monsoon Communications

Tel: +61 (0)3 9620 3333

rudim@monsoon.com.au

## **ABOUT EXOPHARM**

Exopharm Limited (ASX:EX1) is a clinical-stage biopharmaceutical company at the forefront of transformative medicines using exosomes, or extracellular vesicles (EVs), and is pursuing a pipeline-driven platform strategy.

Exosomes can be loaded with a variety of active pharmaceutical ingredients (APIs) and can be targeted to selected cell and tissue types (tropism) – improving the safety -profile of the APIs and providing better treatments.

Exosome delivery of DNA and other gene therapies into the nucleus of the patient's cells can improve treatment of inherited medical conditions.

Exosomes are an alternative means of drug delivery inside the body, alongside technologies such as lipid nanoparticles (LNP), cell-penetrating peptides, viral vectors and liposomes. The drug delivery industry is growing at a compound annual growth rate (CAGR) of 5% and is currently valued at about US\$175 billion (\$233 billion).

Exopharm's exosome technologies meet important needs for the success of exosome medicines – **LEAP** manufacturing technology, **LOAD** API loading and **EVPS** tropism.

Exopharm's suite of exosome technologies enables its own pipeline of exosome medicines – each aimed at delivering a transformative medicine for an unmet medical need.

Exopharm's intellectual property is also available under licences or partnerships to empower others to build their pipelines around the benefits of exosome medicines.

## **FORWARD LOOKING STATEMENTS**

This announcement contains forward-looking statements which incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets', 'aims', 'plans' or 'expects'. These statements are based on an evaluation of current corporate estimates, economic and operating conditions, as well as assumptions regarding future events. These events are, as at the date of this announcement, expected to take place, but there cannot be any guarantee that such events will occur as anticipated or at all given that many of the events are outside of Exopharm's control or subject to the success of the Development Program. Furthermore, the Company is subject to several risks as disclosed in the Prospectus dated 6 November 2018.